Now showing items 1-10 of 27
How Did the 2003 Prescription Drug Re-Importation Bill Pass the House?
the major interest groups in the debate over allowing the re-importation of prescription drugs by utilizing a logit model and instrumental variables. Consistent with political support approach, the evidence suggests that ...
Effective Patent Life in Pharmaceuticals
(International Journal of Technology Management, 2000)
Economics of new oncology drug development.
(J Clin Oncol, 2007-01-10)
PURPOSE: Review existing studies and provide new results on the development, regulatory, and market aspects of new oncology drug development. METHODS: We utilized data from the US Food and Drug Administration (FDA), company ...
Encouraging the Development of New Vaccines
(Health Affairs, 2005)
The Ripple Effects of a Restrictive Medicaid Formulary (editorial)
(American Journal of Managed Care, 2003-10)
Generic Competition in the U.S. Pharmaceutical Industry
(International Journal of the Economics of Business, 2006-02)
How did the 2003 prescription drug re-importation bill pass the house?
(Economics and Politics, 2006-03-01)
We examine the major interest groups in the debate over allowing the re-importation of prescription drugs by utilizing a logit model and instrumental variables. Consistent with political support approach, the evidence suggests ...
Entry and competition in generic biologics
(Managerial and Decision Economics, 2007-06-01)
Patents for several blockbuster biological products are expected to expire soon. The Food and Drug Administration is examining whether biologies can and should be treated like pharmaceuticals with regard to generics. In ...
The Determinants of Pharmaceutical Research and Development Expenditures
(Journal of Evolutionary Economics, 2000)
Do Faster FDA Drug Reviews Adversely Affect Patient Safety? An Analysis of the 1992 Prescription Drug User Fee Act
times have significantly declined since the passage of PDUFA in 1992, while agency resources have expanded through user fees. After the recent withdrawal of Vioxx and other high-profile products, there have been increasing ...